Device Trial Radar · NCT06668935
Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
Oct 24, 2024
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Abbott Diabetes CarePublic (ABT)
- Sponsor type
- Industry
- First posted
- Nov 1, 2024
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to see if the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) will help prolong the length of time people with diabetes maintain adherence to glucagon-like peptide 1 (GLP-1/GIP) agonists.
Conditions
- Diabetes Mellitus
Interventions
To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonistsDevice
All subjects will then begin use of their prescribed GLP-1 or combination GIP/GLP-1 medication in accordance with the HCP's instructions. Subjects will be titrated to their maximum tolerable dose per the medication's approved titration schedule and according to their HCP's standard of care between Visits 2 and 3.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the length of time subjects in each group remain on a GLP-1 or GLP-1/GIP combination drugTime frame: 210 days
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Helios Clinical Research
Paradise Valley, Arizona · Recruiting
East Coast Institute for Research, LLC
Jacksonville, Florida · Recruiting
Excellence Medical and Research
Miami Gardens, Florida · Recruiting
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.